<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Response to: &apos;Let&apos;s stop fooling ourselves. In RA, only ACR/EULAR criteria define remission and equate with absence of disease!&apos; by Boers</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2016-08-12">12 August 2016</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><roleName>Professor</roleName><forename type="first">Paul</forename><surname>Emery</surname></persName>
							<email>p.emery@leeds.ac.uk</email>
							<affiliation key="aff0">
								<orgName type="department">Leeds Institute of Rheumatic and Musculoskeletal Medicine</orgName>
								<orgName type="institution">University of Leeds</orgName>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="institution" key="instit1">NIHR Leeds Musculoskeletal Biomedical Research Unit</orgName>
								<orgName type="institution" key="instit2">Leeds Teaching Hospitals NHS Trust</orgName>
								<address>
									<settlement>Leeds</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">C</forename><forename type="middle">O</forename><surname>Bingham</surname><genName>III</genName></persName>
							<affiliation key="aff2">
								<orgName type="institution">John Hopkins University</orgName>
								<address>
									<settlement>Baltimore</settlement>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">G</forename><forename type="middle">R</forename><surname>Burmester</surname></persName>
							<affiliation key="aff3">
								<orgName type="institution">Charité -University Medicine</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">V</forename><forename type="middle">P</forename><surname>Bykerk</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Division of Rheumatology, Hospital for Special Surgery</orgName>
								<orgName type="institution">Weill Cornell Medical College</orgName>
								<address>
									<region>New York</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Furst</surname></persName>
							<affiliation key="aff5">
								<orgName type="department" key="dep1">Division of Rheumatology</orgName>
								<orgName type="department" key="dep2">David Geffen School of Medicine at UCLA</orgName>
								<address>
									<settlement>Los Angeles</settlement>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">X</forename><surname>Mariette</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">INSERM U1184</orgName>
								<orgName type="institution" key="instit1">Université Paris-Sud</orgName>
								<orgName type="institution" key="instit2">Hôpitaux Universitaires Paris-Sud, AP-HP</orgName>
								<address>
									<settlement>Le Kremlin Bicêtre</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">D</forename><surname>Van Der Heijde</surname></persName>
							<affiliation key="aff7">
								<orgName type="institution">Leiden University Medical Centre</orgName>
								<address>
									<settlement>Leiden</settlement>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">R</forename><surname>Van Vollenhoven</surname></persName>
							<affiliation key="aff8">
								<orgName type="department">Inflammatory Disease</orgName>
								<orgName type="laboratory">Unit for Clinical Therapy Research</orgName>
								<orgName type="institution">Karolinska Institute</orgName>
								<address>
									<settlement>Stockholm</settlement>
									<country key="SE">Sweden</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">C</forename><surname>Arendt</surname></persName>
							<affiliation key="aff9">
								<orgName type="institution">UCB Pharma</orgName>
								<address>
									<settlement>Brussels</settlement>
									<country key="BE">Belgium</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">I</forename><surname>Mountian</surname></persName>
							<affiliation key="aff9">
								<orgName type="institution">UCB Pharma</orgName>
								<address>
									<settlement>Brussels</settlement>
									<country key="BE">Belgium</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">O</forename><surname>Purcaru</surname></persName>
							<affiliation key="aff9">
								<orgName type="institution">UCB Pharma</orgName>
								<address>
									<settlement>Brussels</settlement>
									<country key="BE">Belgium</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">D</forename><surname>Tatla</surname></persName>
							<affiliation key="aff10">
								<orgName type="institution">UCB Pharma</orgName>
								<address>
									<settlement>Raleigh</settlement>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">B</forename><surname>Vanlunen</surname></persName>
							<affiliation key="aff10">
								<orgName type="institution">UCB Pharma</orgName>
								<address>
									<settlement>Raleigh</settlement>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Weinblatt</surname></persName>
							<affiliation key="aff11">
								<orgName type="department" key="dep1">Division of Rheumatology, Immunology and Allergy</orgName>
								<orgName type="department" key="dep2">Brigham and Women&apos;s Hospital</orgName>
								<address>
									<settlement>Boston</settlement>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff12">
								<orgName type="institution" key="instit1">Leeds Institute of Rheumatic and Musculoskeletal Medicine</orgName>
								<orgName type="institution" key="instit2">University of Leeds</orgName>
								<orgName type="institution" key="instit3">Chapel Allerton Hospital</orgName>
								<address>
									<addrLine>Chapeltown Road</addrLine>
									<postCode>LS7 4SA</postCode>
									<settlement>Leeds</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Response to: &apos;Let&apos;s stop fooling ourselves. In RA, only ACR/EULAR criteria define remission and equate with absence of disease!&apos; by Boers</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2016-08-12">12 August 2016</date>
						</imprint>
					</monogr>
					<idno type="MD5">26693031C1863F15BBE493849A22DB35</idno>
					<idno type="DOI">10.1136/annrheumdis-2016-210063</idno>
					<note type="submission">Received 2 July 2016 Accepted 3 July 2016</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:21+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Provenance and peer review Commissioned; internally peer reviewed.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>We would like to thank Dr Boers for his critical comments on our study raised in his eLetter, <ref type="bibr" target="#b0">1</ref> and address his concerns regarding our manuscript. <ref type="bibr" target="#b1">2</ref></s><s>irst, we would like to emphasise that we are in support of the statements in the guidelines issued by the American College of Rheumatology/European League Against Rheumatism (ACR/ EULAR) in early 2011, <ref type="bibr" target="#b2">3</ref> and acknowledge that the Disease Activity Score 28 erythrocyte sedimentation rate (DAS28(ESR)) based definition of clinical remission (DAS28(ESR) &lt;2.6) is less stringent than the simple disease activity index (SDAI)-and Boolean-based definitions.</s></p><p><s>However, our manuscript does not make any claims that DAS28(ESR)-based remission is reflective of 'true' or 'real' remission or the absence of disease.</s><s>Our methods and figures state clearly that our study used the DAS28(ESR)-based remission criterion.</s><s>Furthermore, the manuscript also reports the proportion of patients who achieved SDAI-based remission ( please see figure 4A in the paper) as a secondary endpoint, which was achieved by more certolizumab pegol (CZP)+methotrexate (MTX) treated patients than placebo (PBO)+MTX-treated patients ( p&lt;0.001 [nominal p-value]). <ref type="bibr" target="#b1">2</ref></s><s>he protocol for the certolizumab pegol effective in early rheumatoid arthritis (C-EARLY) study was developed prior to the issue of the 2011 ACR/EULAR guidelines.</s><s>At this time in 2010, DAS28(ESR) &lt;2.6 was still acknowledged as both a validated and clinically relevant definition of disease remission for treatment with biological disease-modifying antirheumatic drugs. <ref type="bibr">4 5</ref></s><s>In our study, we clearly define sustained remission as DAS28(ESR) &lt;2.6 at both weeks 40 and 52.</s><s>Maintenance of disease remission is a highly relevant clinical goal for patients with chronic disease.</s><s>However, it is rarely used in clinical trials because it is difficult to achieve.</s><s>Despite this, we employed sustained disease remission as our primary endpoint in C-EARLY.</s><s>This endpoint was not chosen because it was easy to achieve; it was chosen for its high level of stringency and relevance to patient care.</s><s>Furthermore, as previous RA trials have used DAS based measures of low disease activity (LDA) and remission, techniques such as meta-analyses can applied to compare the results described in our article with other published studies.</s></p><p><s>The C-EARLY study was designed to have an additional, extended component (NCT01521923), <ref type="bibr" target="#b5">6</ref> which evaluated the efficacy and safety of either stopping, continuing or reducing the frequency of CZP dosage over an additional year (weeks 52-104).</s><s>An important component for C-EARLY Period 2 was the evaluation of disease flares.</s><s>To ensure standardisation of the definition of a flare, we followed the Outcome Measures in Rheumatoid Arthritis Clinical Trials rheumatoid arthritis flare guidelines, which uses changes in DAS28(ESR) scores to evaluate disease worsening. <ref type="bibr" target="#b6">7</ref></s><s>In order to maintain consistency between the two parts of the study, and evaluate disease activity with clinical targets such as LDA and remission, we used DAS28 (ESR)-based definitions in both periods of the C-EARLY study as primary endpoints.</s></p><p><s>We agree with Dr Boers that the SDAI-and Boolean-based definitions of remission now supersede the previous DAS28 (ESR)-based standard and we support the statement that, where appropriate, future clinical trials in rheumatoid arthritis should adhere to the recommendations issued by ACR and EULAR.</s></p></div>		</body>
		<back>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Let&apos;s stop fooling ourselves. In RA, only ACR/EULAR criteria define remission and equate with absence of disease</title>
		<author>
			<persName><forename type="first">M</forename><surname>Boers</surname></persName>
		</author>
		<idno type="DOI">10.1136/annrheumdis-2016-210063</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">75</biblScope>
			<biblScope unit="page">e68</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study</title>
		<author>
			<persName><forename type="first">P</forename><surname>Emery</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">O</forename><surname>Bingham</surname></persName>
		</author>
		<author>
			<persName><surname>Iii</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">R</forename><surname>Burmester</surname></persName>
		</author>
		<idno type="DOI">10.1136/annrheumdis-2015-209057</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">T</forename><surname>Felson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Smolen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Wells</surname></persName>
		</author>
		<idno type="DOI">10.1136/ard.2011.149765</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">70</biblScope>
			<biblScope unit="page" from="404" to="413" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Smolen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Landewe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">C</forename><surname>Breedveld</surname></persName>
		</author>
		<idno type="DOI">10.1136/ard.2009.126532</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="page" from="964" to="975" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Treating rheumatoid arthritis to target: recommendations of an international task force</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Smolen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Aletaha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jwj</forename><surname>Bijlsma</surname></persName>
		</author>
		<idno type="DOI">10.1136/ard.2009.123919</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="page" from="631" to="637" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">A Randomized Double-Blind Treatment Strategy Study Evaluating Continuation or Reduced-Frequency Dosing of Certolizumab Pegol Versus Withdrawal to Maintain Low Disease Activity in Early RA Patients (C-EARLY Period 2)</title>
		<author>
			<persName><forename type="first">P</forename><surname>Emery</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">O</forename><surname>Bingham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">R</forename><surname>Burmester</surname></persName>
		</author>
		<idno type="DOI">10.1136/annrheumdis-2016-209124.34</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">75</biblScope>
			<biblScope unit="page">143</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Identifying flares in rheumatoid arthritis: reliability and construct validation of the OMERACT RA Flare Core Domain Set</title>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">P</forename><surname>Bykerk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">O</forename><surname>Bingham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">H</forename><surname>Choy</surname></persName>
		</author>
		<idno type="DOI">10.1136/rmdopen-2015-000225</idno>
	</analytic>
	<monogr>
		<title level="j">RMD Open</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page">e000225</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
